phone

House Dust Mite Allergy - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 43
  • Category: Pharmaceuticals
  • Country: Global
House Dust Mite Allergy - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2017, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 2 and 1 respectively.

House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction
Global Markets Direct Report Coverage
House Dust Mite Allergy - Overview
House Dust Mite Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
House Dust Mite Allergy - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
House Dust Mite Allergy - Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergy Therapeutics Plc
Anergis SA
Biomay AG
Stallergenes Greer plc
Zhejiang I-Biological Technology Co Ltd
House Dust Mite Allergy - Drug Profiles
Acarovac Quattro - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AllerDM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
House Dust Mite Allergy - Dormant Projects
House Dust Mite Allergy - Discontinued Products
House Dust Mite Allergy - Product Development Milestones
Featured News & Press Releases
May 04, 2017: ALKs HDM SLIT-tablet, ACARIZAX, approved in Canada
Apr 16, 2017: ACARIZAX approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis
Mar 01, 2017: FDA approves Odactra for house dust mite allergies
Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval
Jan 27, 2017: Stallergenes Greer Announces Positive Top-Line Results Of Phase 3 Study For Pediatric House Dust Mite-Induced Allergic Rhinitis
Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX
Apr 13, 2016: License application for investigational house dust mite SLIT-tablet accepted for review by FDA
Apr 12, 2016: Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet
Apr 05, 2016: Stallergenes Greer Announces The Approval Of Actair In Australia
Jan 27, 2016: Marketing authorisation for ACARIZAX issued in France
Dec 09, 2015: New product (ACARIZAX) for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark
Nov 26, 2015: New medicine for house dust mite allergic rhinitis now available in Japan
Nov 19, 2015: Desensitization Therapy Actair House Dust Mite Sublingual Tablets Launched in Japan
Sep 28, 2015: ALKs partner, Torii, obtains approval for the house dust mite SLIT-tablet in Japan
Jun 09, 2015: ALKs partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for House Dust Mite Allergy, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H2 2017
House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, H2 2017
House Dust Mite Allergy - Pipeline by Anergis SA, H2 2017
House Dust Mite Allergy - Pipeline by Biomay AG, H2 2017
House Dust Mite Allergy - Pipeline by Stallergenes Greer plc, H2 2017
House Dust Mite Allergy - Pipeline by Zhejiang I-Biological Technology Co Ltd, H2 2017
House Dust Mite Allergy - Dormant Projects, H2 2017
House Dust Mite Allergy - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for House Dust Mite Allergy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

House Dust Mite Allergy - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2017, provides an overview

View Report

Top Trends in Household Cleaning and Laundry 2017: The latest trends in the air freshener, dishwashing product, general purpose household cleaner, laundry care, household paper towels and pest control categories Top

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports